Distribution-based estimates of minimum clinically important difference in cognition, arm function and lower body function after slow release-fampridine treatment of patients with multiple sclerosis.
Mult Scler Relat Disord
; 7: 58-60, 2016 May.
Article
em En
| MEDLINE
| ID: mdl-27237758
ABSTRACT
OBJECTIVE:
To provide distribution-based estimates of the minimal clinical important difference (MCID) after slow release fampridine treatment on cognition and functional capacity in people with MS (PwMS).METHOD:
MCID values were determined after SR-Fampridine treatment in 105 PwMS. Testing included the Timed 25 Foot Walk (T25FW), the Symbol Digit Modalities Test (SDMT), the Six Spot Step Test (SSST), the 9-Hole-Peg-Test (9-HPT), and the 5-Time-Sit-To-Stand test (5-STS).RESULTS:
MCID values T25FW 17.8% (9.1-17.8), SDMT 17.1% (9.2-17.1), SSST 16.7% (8.5-16.7), 9-HPT 15.3% (0-15.3), and 5-STS 34.6% (16.9-34.6).CONCLUSION:
This study presents distribution-based estimates of MCID values for the SSST, the 9-HPT, and the 5-STS and confirms MCID estimates for the T25FW and the SDMT.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
4-Aminopiridina
/
Cognição
/
Bloqueadores dos Canais de Potássio
/
Avaliação da Deficiência
/
Atividade Motora
/
Esclerose Múltipla
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Mult Scler Relat Disord
Ano de publicação:
2016
Tipo de documento:
Article